课题基金 / 基金详情

Adapting Diabetes Treatment Expert Systems to Patient's Expectations and Psychobehavioral Characteristics in Type 1 Diabetes

Adapting Diabetes Treatment Expert Systems to Patient's Expectations and Psychobehavioral Characteristics in Type 1 Diabetes
使糖尿病治疗专家系统适应 1 型糖尿病患者的期望和心理行为特征
批准号:
10348116
负责人:
MARC D BRETON
金额:
$65.73万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-07-24 至 2024-01-31

项目摘要

项目成果

MARC D BRETON的其他基金

相似基金

相关文献

中文摘要
翻译
使糖尿病治疗专家系统适应患者的期望和心理行为 1型糖尿病的治疗方法 1型糖尿病(T1 DM)中的葡萄糖变异性(GV)通常被视为血糖控制的主要标志物, 可能与慢性高血糖症一起沿着导致糖尿病并发症。本拟议项目 继续20年的研究,确定了GV的生理和行为相关性,并成功地 测试反馈控制策略,通过同时预防低血糖和系统性 T1 DM高血糖症。 我们的主要假设是:降低T1 DM中的葡萄糖变异性可以通过技术实现最佳效果 其被告知并适应于患者/用户的个体心理行为和代谢概况。这 可以通过个性化和自动调整治疗策略来实现, 与每位患者的技术接受水平相对应的干预,旨在最大限度地 通过跟踪和加强对干预的信任,成功使用系统。 因此,在本项目中,我们计划(i)确认先前设计的两种技术干预措施的有效性 - 信息决策支持系统(iDSS)和规定性决策支持系统(pDSS)-减少 在一项为期6个月的随机交叉临床试验中,T1 DM患者的GV;(ii)显示受试者 参与本研究的人员将具有可预测的技术干预偏好(例如,iDSS与pDSS) 通过他们的心理行为特征的关键参数,并通过以下方式预测GV控制水平: 干预;最后,我们建议定义和验证一个新的,可测量的,技术指数 接受和信任,通过自动观察用户/系统交互。 总之,本项目将证明,基于CGM的决策支持系统可以显着减少 GV在T1 DM中的作用,并且该性能通过心理行为特征和期望来预测。我们 进一步引入了一种新颖的指标跟踪技术,即接受度和信任度,预测系统性能。 这种指数最终将使未来的自动化治疗策略的最佳自适应。
英文摘要
Adapting Diabetes Treatment Expert Systems to Patient's Expectations and Psychobehavioral Characteristics in Type 1 Diabetes. Glucose variability (GV) in type 1 diabetes (T1DM) is commonly viewed as a primary marker of glycemic control, potentially responsible, along with chronic hyperglycemia, for diabetes complications. This proposed project continues 20 years of research, which identified physiological and behavioral correlates of GV and successfully tested feedback control policies to reduce GV via simultaneous protection against hypoglycemia and systematic hyperglycemia in T1DM. Our primary hypothesis is that: Reducing glucose variability in T1DM can be optimally achieved by technology that is informed of, and adapted to, the individual psychobehavioral and metabolic profiles of patients/users. This can be achieved through personalization and automated adaptation of treatment policies, and through treatment intervention that corresponds to each patient's level of technology acceptance and is designed to maximize successful system use by tracking and reinforcing trust in the intervention. Therefore, in this project we plan to (i) confirm the efficacy of two previously designed technological interventions - Informative Decision Support System (iDSS) and Prescriptive Decision Support System (pDSS) - in reducing GV in T1DM patients during a 6-month long randomized cross-over clinical trial; (ii) show that subjects participating in this study will have technology intervention preferences (e.g. iDSS vs pDSS) that can be predicted by key parameters of their psychobehavioral profile and are prognostic of the level of GV control achievable by the intervention; and finally, we propose to define and validate a novel, measureable, index of technology acceptance and trust, by automatically observing user/system interactions. In summary, this project will demonstrate that CGM-based decision support systems can significantly reduce GV in T1DM, and that performance is predicted by psychobehavioral characteristics and expectations. We further introduce a novel index tracking technology acceptance and trust, predictive of system performance. Such index would ultimately enable future optimal self-adaptation of automated treatment strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
  • 批准号:
    10676903
  • 项目类别:
  • 资助金额:
    $65.8万
  • 财政年份:
    2021
  • 负责人:
    MARC D BRETON
  • 依托单位:
Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
  • 批准号:
    10276560
  • 项目类别:
  • 资助金额:
    $68.6万
  • 财政年份:
    2021
  • 负责人:
    MARC D BRETON
  • 依托单位:
Advanced Artificial Pancreas Systems to Enable Fully Automated Glycemic Control in Type 1 Diabetes Mellitus
  • 批准号:
    10488207
  • 项目类别:
  • 资助金额:
    $67.18万
  • 财政年份:
    2021
  • 负责人:
    MARC D BRETON
  • 依托单位:
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis